IVVD

Invivyd Inc

0.7212

Oct 09 • 3:59 PM ET +0.0208 (2.97%)

0.7301

Aftermarket • 7:53 PM ET +0.0089 (1.23%)

Healthcare Biotechnology USA Micro NASD

Peers: INCY BMRN KRYS KYMR RYTM CRNX AXSM MDGL VKTX NBIX

| Held by: VTI IWM VXF IWN VTWO IWC ITOT BBC PRFZ VTWV

Scroll to Statements

Index	RUT
Market Cap	212.58M
Enterprise Value	60.89M
Income	-107.33M
Sales	58.37M
Book/sh	0.61
Cash/sh	0.54
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	122
IPO	Aug 06, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	3.64
P/B	1.17
P/C	1.33
P/FCF	-
EV/EBITDA	-
EV/Sales	1.04
Quick Ratio	5.86
Current Ratio	5.87
Debt/Eq	0.05
LT Debt/Eq	0.04
Option/Short	Yes / Yes

EPS (ttm)	-0.37
EPS next Y	-0.33
EPS next Q	-0.13
EPS this Y	-75.56%
EPS next Y	37.97%
EPS next 5Y	19.51%
EPS past 3/5Y	48.48% 12.29%
Sales past 3/5Y	- -
EPS Y/Y TTM	59.47%
Sales Y/Y TTM	26.30%
EPS Q/Q	-13.34%
Sales Q/Q	21.20%
Earnings	Aug 13 AMC
EPS/Sales Surpr.	-31.21% -0.81%

Insider Own	11.23%
Insider Trans	-0.68%
Inst Own	78.11%
Inst Trans	-5.19%
ROA	-69.69%
ROE	-95.89%
ROIC	-57.14%
Gross Margin	88.78%
Oper. Margin	-192.81%
Profit Margin	-183.90%
SMA20	-14.59%
SMA50	-11.39%
SMA200	-44.87%
Trades

Shs Outstand	294.76M
Shs Float	261.67M
Short Float	12.94%
Short Ratio	6.96
Short Interest	33.86M
52W High	3.07 -76.51%
52W Low	0.53 36.67%
Volatility	8.81% 10.37%
ATR (14)	0.08
RSI (14)	40.57
Beta	1.14
Rel Volume	0.57
Avg Volume	4.86M
Volume	2,767,115

Perf Week	-12.27%
Perf Month	-7.05%
Perf Quarter	-8.42%
Perf Half Y	-59.02%
Perf YTD	-70.80%
Perf Year	-61.84%
Perf 3Y	-56.29%
Perf 5Y	-97.90%
Perf 10Y	-
Recom	1.00
Target Price	10.00
Prev Close	0.70
Price	0.72
Change %	2.97%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-22-25	Initiated	BTIG Research	Buy	$10
Nov-25-25	Downgrade	D. Boral Capital	Buy → Hold
Oct-06-25	Initiated	Cantor Fitzgerald	Overweight	$10
Apr-05-24	Upgrade	Guggenheim	Neutral → Buy	$9
Mar-26-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$4 → $10
Dec-19-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$1 → $4
May-01-23	Initiated	H.C. Wainwright	Buy	$5

Oct-05-26 07:01AM	Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-30-26 12:19PM	Invivyds Covid-directed mAb hits Phase III safety goals (Clinical Trials Arena)
Sep-29-26 10:40AM	Invivyd Reports Positive Phase 3 LIBERTY Results for VYD2311 and Plans Accelerated Approval Submission (InvestorsHub) -10.52%
07:01AM	Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311 (GlobeNewswire)
Sep-21-26 05:06PM	These beaten-down stocks could bounce back in January, if history is any guide (MarketWatch) +35.05% -5.49%
07:01AM	Loading…
Sep-03-26 07:01AM	Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-01-26 07:01AM	Invivyd Appoints Chairman Marc W. Elia as Chief Executive Officer; Approaches Results of VYD2311 studies DECLARATION and LIBERTY (GlobeNewswire) -7.85%
Aug-13-26 04:05PM	Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights (GlobeNewswire) -6.33% +5.13%
Aug-04-26 07:01AM	Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-06-26 01:39PM	IVVD Stock Drops As PEMGARDA Loses Emergency Authorization In 2027 Invivyd Eyes Full FDA Approval (Stocktwits) -6.69%
07:01AM	Invivyd Announces Receipt of Twelve Months' Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA and Provides an Update on Next Steps with the U.S. FDA (GlobeNewswire)
Jul-02-26 07:01AM	Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-16-26 07:01AM	Invivyd Announces Completion of Enrollment in Phase 3 LIBERTY Trial Evaluating VYD2311 Antibody Versus mRNA COVID-19 Vaccine (GlobeNewswire)
Jun-09-26 12:22PM	Invivyd doses first participants in Phase 3 COVID-19 trial (Proactive)
07:01AM	Invivyd Announces First Participants Dosed in LIBERTY, a Phase 3 Clinical Trial to Evaluate the Safety and Tolerability of VYD2311 Antibody Versus mRNA COVID Vaccine and to Characterize the Safety and Immunology of Antibody and mRNA Vaccine Co-Administration (GlobeNewswire)
07:01AM	Loading…
Jun-03-26 07:01AM	Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-01-26 07:01AM	Invivyd Announces Completion of Enrollment in Upsized DECLARATION Clinical Trial, a Phase 3 Pivotal Study of VYD2311, an Investigational Antibody to Prevent COVID (GlobeNewswire) +7.02%
May-27-26 07:01AM	Invivyd to Participate in Upcoming Investor Events (GlobeNewswire)
May-14-26 07:01PM	Invivyd Inc (IVVD) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Investments (GuruFocus.com) -21.09%
07:01AM	Invivyd Reports First Quarter 2026 Financial Results and Recent Business Highlights (GlobeNewswire)
May-11-26 07:01AM	Invivyd and Collaborators Author New Manuscript Evaluating Early Tolerability of COVID Monoclonal Antibody and Comparing Results to COVID Vaccination (GlobeNewswire)
May-07-26 07:01AM	Invivyd to Host First Quarter 2026 Financial Results and Corporate Update Call on May 14, 2026 (GlobeNewswire)
May-05-26 07:01AM	Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.44%
Apr-20-26 07:01AM	Invivyd Announces Chairman Marc Elia to Speak at POLITICO Health Care Summit (GlobeNewswire)
Apr-09-26 07:01AM	Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and Best-in-Class Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of Measles (GlobeNewswire) +31.85%
Apr-07-26 07:01AM	Invivyd Launches "Antibodies for Any Body" in Partnership with World Champion Skier Lindsey Vonn to Inspire Actions that Help Support Immune Health (GlobeNewswire)
Apr-06-26 07:01AM	Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-30-26 04:05PM	Invivyd Announces Presentation at the World Vaccine Congress Washington (GlobeNewswire) -13.14% +9.24%
Mar-05-26 09:07PM	Invivyd Q4 Earnings Call Highlights (MarketBeat)
04:02PM	Invivyd Inc (IVVD) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
12:36PM	Loading…
12:36PM	Invivyd, Inc. Q4 2025 Earnings Call Summary (Moby)
07:03AM	Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates (GlobeNewswire)
07:01AM	Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer (GlobeNewswire)
Mar-02-26 04:10PM	Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026 (GlobeNewswire) -5.81%
04:01PM	Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-26-26 12:15PM	MannKind (MNKD) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
Feb-24-26 07:01AM	New Publication Demonstrates Variant-Agnostic Correlate of Protection from COVID-19 for Invivyd Monoclonal Antibody, Useful for Understanding of and Confidence in COVID-19 Antibodies (GlobeNewswire)
Feb-17-26 05:10PM	Halozyme Therapeutics (HALO) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +6.45%
Feb-03-26 07:01AM	Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration (GlobeNewswire) +8.05%
Jan-22-26 07:01AM	Invivyd Announces Partnership with World Champion Skier Lindsey Vonn to Educate Americans on Antibodies and Disease Prevention (GlobeNewswire)
Jan-20-26 07:01AM	Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026 (GlobeNewswire) -8.57%
Jan-14-26 02:13PM	?Invivyd (IVVD) Reports Strong Q4 Growth, Advances COVID Antibody to Phase 3 (Insider Monkey) +11.11%
Jan-08-26 07:01AM	Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights (GlobeNewswire)
Dec-31-25 11:13AM	BTIG Initiates Invivyd (IVVD) Coverage, Cites VYD2311's Superior Market Potential Over Pemgarda (Insider Monkey)
Dec-23-25 07:05AM	Invivyd Earns Fast Track Designation for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID (GlobeNewswire)
07:01AM	Invivyd Announces Initiation of DECLARATION Clinical Trial, a Phase 3 Placebo-Controlled Pivotal Study of VYD2311, a Vaccine-Alternative Antibody to Prevent COVID (GlobeNewswire)
Dec-22-25 09:47AM	Arcellx initiated, Cummins upgraded: Wall Street's top analyst calls (The Fly) +25.22%
Dec-18-25 01:14AM	Invivyd, Inc. (IVVD): Advancing RSV Antibody VBY329 Amid Analyst Downgrade (Insider Monkey)
Nov-25-25 07:01AM	Invivyd to Participate at the 8th Annual Evercore Healthcare Conference (GlobeNewswire) -5.42%
Nov-24-25 07:01AM	Invivyd Announces Selection of Potential Best-In-Class RSV Antibody Candidate VBY329; Targeting 2H 2026 IND Readiness (GlobeNewswire)
Nov-17-25 10:40PM	Invivyd Announces Pricing of $125 Million Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) +20.85% -10.92%
04:01PM	Invivyd Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Nov-06-25 09:15AM	Invivyd, Inc. (IVVD) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:01AM	Invivyd Reports Third Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
Nov-05-25 07:52AM	Invivyd Inc (IVVD) Q3 2025 Earnings Report Preview: What to Expect (GuruFocus.com) +8.57%
07:40AM	Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
Nov-04-25 10:00AM	Viridian Therapeutics, Inc. (VRDN) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks) -13.04%
Nov-03-25 04:01PM	Invivyd to Host Third Quarter 2025 Financial Results and Corporate Update Call on November 6, 2025 (GlobeNewswire) -8.52%
Oct-28-25 07:01AM	Invivyd to Host Webcast on the REVOLUTION Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID (GlobeNewswire)
Oct-06-25 07:01AM	Invivyd Announces U.S. IND Clearance and Alignment with U.S. FDA on Pivotal Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID (GlobeNewswire) +22.41%
Sep-24-25 04:01PM	Invivyd Appoints Paul B. Bolno, M.D. to Its Board of Directors (GlobeNewswire) +5.17% -6.56%
Sep-23-25 07:25PM	Invivyd, Inc. (IVVD) Secures FDA Path for COVID-19 Antibody Approval (Insider Monkey)
Sep-17-25 07:01AM	Invivyd Announces Appointment of Kristie Kuhl as Chief Communications Officer (GlobeNewswire) -8.73%
Sep-04-25 07:01AM	SPEAR Study Group to Present its Recommended Long COVID Antibody Study Design Featuring Invivyd's VYD2311 At RECOVER-TLC Workshop September 9-10, 2025 (GlobeNewswire)
Aug-27-25 07:01AM	Invivyd to Participate in Upcoming Investor Conferences (GlobeNewswire) -15.44%
Aug-26-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +84.03%
Aug-22-25 12:00PM	Invivyd Announces Closing of $57.5 Million Public Offering and Full Exercise of the Underwriter's Option to Purchase Additional Shares (GlobeNewswire)
Aug-20-25 11:58PM	Invivyd Announces Pricing of $50 Million Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) +11.00% -16.71%
04:01PM	Invivyd Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Aug-18-25 04:32PM	Invivyd Announces Continued Neutralizing Activity of PEMGARDA (pemivibart) and VYD2311 Against Currently Dominant SARS-CoV-2 Variant XFG ("Stratus") (GlobeNewswire) -17.82%
Aug-14-25 06:00PM	Invivyd, Inc. (IVVD) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -11.54%
04:49PM	Invivyd Reports Second Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
04:47PM	Invivyd Aligns with U.S. FDA on Rapid Pathway to Full Approval (BLA) of Vaccine Alternative Monoclonal Antibody VYD2311 to Protect American Adults and Adolescents from COVID-19 (GlobeNewswire)
Aug-12-25 05:40PM	Armata Pharmaceuticals, Inc. (ARMP) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
Aug-08-25 05:30AM	The Race to Find a Measles Treatment as Infections Surge (The Wall Street Journal) +5.88%
Aug-07-25 06:15PM	Alector (ALEC) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +5.10%
Aug-06-25 08:20AM	Royalty Pharma (RPRX) Tops Q2 Earnings and Revenue Estimates (Zacks)
Jul-23-25 07:01AM	Scientist Dr. Akiko Iwasaki Joins SPEAR Study Group to Investigate Monoclonal Antibodies for Long COVID and COVID-19 Post-Vaccination Syndrome (GlobeNewswire) +5.26%
Jul-21-25 07:05AM	National Comprehensive Cancer Network (NCCN) Guidelines Recommend Monoclonal Antibodies for COVID-19 Prevention in People with Cancer; New Data Published in JAMA Oncology Underscore Severe Impact of COVID-19 on This Population (GlobeNewswire)
Jul-02-25 07:01AM	Invivyd and Leading Researchers Form SPEAR (Spike Protein Elimination and Recovery) Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long COVID and COVID-19 Post-Vaccination Syndrome (GlobeNewswire)
Jun-26-25 07:01AM	Invivyd Announces Positive Full Phase 1/2 Clinical Data for VYD2311, a Next Generation COVID-19 Monoclonal Antibody for Potential Use as a Non-Vaccine Preventative and for Treatment of Active Infection (GlobeNewswire) +13.43%
Jun-02-25 03:49AM	COVIDs remaining biotech contenders navigate a dwindling market (Pharma Voice)
May-29-25 02:36PM	H.C. Wainwright Lowers Invivyd (IVVD) PT to $5 Amid Q1 2025 Revenue Shortfall (Insider Monkey)
May-27-25 07:01AM	Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2 Virus (GlobeNewswire) +20.15%
May-23-25 07:01AM	Invivyd Announces Inclusion of PEMGARDA (pemivibart) in National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas (GlobeNewswire)
May-21-25 09:30AM	Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19 (GlobeNewswire) -5.52%
May-16-25 03:08AM	Invivyd Inc (IVVD) Q1 2025 Earnings Call Highlights: Strategic Shifts and Financial Discipline ... (GuruFocus.com) +10.33%
01:57AM	Q1 2025 Invivyd Inc Earnings Call (Thomson Reuters StreetEvents)
May-15-25 08:15AM	Invivyd, Inc. (IVVD) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -15.78%
07:01AM	Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
May-14-25 09:53AM	What To Expect From Invivyd Inc (IVVD) Q1 2025 Earnings (GuruFocus.com)
07:01AM	Invivyd Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies For Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy (GlobeNewswire)
May-13-25 07:01AM	Invivyd to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference (GlobeNewswire)
May-12-25 07:01AM	Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles (GlobeNewswire) +29.67%
May-08-25 07:01AM	Invivyd to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025 (GlobeNewswire)
Apr-21-25 09:58AM	What's Going On With Invivyd Stock On Monday? (Benzinga) +10.00%
07:01AM	Invivyd Announces $30M Non-dilutive Loan Facility with Silicon Valley Bank (GlobeNewswire)
Mar-26-25 04:15PM	Invivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of Directors (GlobeNewswire) -6.70%
Mar-20-25 09:25AM	Invivyd, Inc. (IVVD) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
08:01AM	Invivyd Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Recent Business Highlights (GlobeNewswire)

Invivyd, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The firm develops antibodies that can neutralize SARS-CoV-2, SARS-CoV-1, and additional emergent coronaviruses. It offers ADG20, a monoclonal antibody, targeting the spike protein of SARS-CoV-2 and related coronaviruses. The company was founded by Tillman U. Gerngross, Ren Russo and Laura Walker on June 3, 2020 and is headquartered in New Haven, CT.

CEO & Chairperson of the BoardMr. Marc William Elia

M.B.A.Mr. William E. Duke Jr.

Chief Legal Officer & Corporate SecretaryMs. Jill Andersen J.D.

Chief Commercial OfficerMr. Timothy Lee

Chief Scientific OfficerDr. Robert D. Allen Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lee Timothy Edward	Chief Commercial Officer	Aug 17 '26	Sale	0.72	22,355	16,140	197,362	Aug 18 08:10 PM
Lee Timothy Edward	Chief Commercial Officer	Aug 18 '26	Sale	0.84	18,425	15,530	178,937	Aug 18 08:10 PM
Green Julie	Chief Human Resources Officer	Aug 17 '26	Sale	0.72	22,355	16,140	187,362	Aug 18 08:10 PM
Green Julie	Chief Human Resources Officer	Aug 18 '26	Sale	0.84	18,425	15,530	168,937	Aug 18 08:10 PM
Duke William E.	Chief Financial Officer	Aug 17 '26	Sale	0.72	22,355	16,140	187,362	Aug 18 08:10 PM
Duke William E.	Chief Financial Officer	Aug 18 '26	Sale	0.84	18,425	15,530	168,937	Aug 18 08:10 PM
Andersen Jill	Chief Legal Officer, Secretary	Aug 17 '26	Sale	0.72	37,256	26,899	314,480	Aug 18 08:10 PM
Andersen Jill	Chief Legal Officer, Secretary	Aug 18 '26	Sale	0.84	30,706	25,882	283,774	Aug 18 08:10 PM
Allen Robert D. III	Chief Scientific Officer	Aug 17 '26	Sale	0.72	20,679	14,930	195,808	Aug 18 08:10 PM
Allen Robert D. III	Chief Scientific Officer	Aug 18 '26	Sale	0.84	17,043	14,366	178,765	Aug 18 08:10 PM
Lee Timothy Edward	Officer	Aug 17 '26	Proposed Sale	0.72	40,800	29,413		Aug 17 04:06 PM
Green Julie	Officer	Aug 17 '26	Proposed Sale	0.72	40,800	29,413		Aug 17 04:05 PM
Duke William E.	Officer	Aug 17 '26	Proposed Sale	0.72	40,800	29,413		Aug 17 04:05 PM
Andersen Jill	Officer	Aug 17 '26	Proposed Sale	0.72	68,001	49,022		Aug 17 04:05 PM
Allen Robert D. III	Officer	Aug 17 '26	Proposed Sale	0.72	37,741	27,207		Aug 17 04:05 PM
Allen Robert D. III	Chief Scientific Officer	Feb 18 '26	Sale	1.58	19,392	30,597	114,487	Feb 18 08:56 PM
Allen Robert D. III	Chief Scientific Officer	Feb 17 '26	Sale	1.54	18,189	28,004	133,879	Feb 18 08:56 PM
Green Julie	Chief Human Resources Officer	Feb 18 '26	Sale	1.58	20,964	33,077	107,717	Feb 18 08:51 PM
Green Julie	Chief Human Resources Officer	Feb 17 '26	Sale	1.54	19,663	30,273	128,681	Feb 18 08:51 PM
Duke William E.	Chief Financial Officer	Feb 18 '26	Sale	1.58	20,964	33,077	107,717	Feb 18 08:49 PM
Duke William E.	Chief Financial Officer	Feb 17 '26	Sale	1.54	19,663	30,273	128,681	Feb 18 08:49 PM
Lee Timothy Edward	Chief Commercial Officer	Feb 18 '26	Sale	1.58	20,964	33,077	117,717	Feb 18 08:47 PM
Lee Timothy Edward	Chief Commercial Officer	Feb 17 '26	Sale	1.54	19,663	30,273	138,681	Feb 18 08:47 PM
Andersen Jill	Chief Legal Officer, Secretary	Feb 18 '26	Sale	1.58	34,939	55,127	181,736	Feb 18 08:47 PM
Andersen Jill	Chief Legal Officer, Secretary	Feb 17 '26	Sale	1.54	32,771	50,454	216,675	Feb 18 08:47 PM
Green Julie	Officer	Feb 17 '26	Proposed Sale	1.56	39,600	61,776		Feb 17 06:39 PM
Allen Robert D. III	Officer	Feb 17 '26	Proposed Sale	1.56	36,630	57,143		Feb 17 06:36 PM
Lee Timothy Edward	Officer	Feb 17 '26	Proposed Sale	1.56	39,600	61,776		Feb 17 06:32 PM
Duke William E.	Officer	Feb 17 '26	Proposed Sale	1.56	39,600	61,776		Feb 17 06:30 PM
Andersen Jill	Officer	Feb 17 '26	Proposed Sale	1.56	66,000	102,960		Feb 17 06:26 PM
ADIMAB, LLC	10% Owner	Dec 23 '25	Proposed Sale	3.00	192,320	577,498		Dec 23 04:23 PM
MCLAUGHLIN KEVIN F	Director	Nov 19 '25	Buy	2.50	50,000	125,000	50,000	Nov 20 04:22 PM
ADIMAB, LLC	10% Owner	Nov 17 '25	Proposed Sale	3.00	1,233,416	3,703,455		Nov 17 04:36 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IVVD

Invivyd Inc

Upgrade your Finviz experience